INNOVADERM CRO IS NOW INDERO.

Thank You!

Your request for information about Indero’s site selection services has been received.

One of our team members will be in touch with you shortly to provide the details you need.

In the meantime...

Stay connected and informed by subscribing to our newsletter for updates, insights, and industry news.

Subscribe to Our Newsletter 👉

This field is for validation purposes and should be left unchanged.

Need Immediate Assistance?

📧 Email: 

[email protected]

 

📞 Phone Numbers:
• North America: 1-866-575-3111
• Spain: +34 931 22 48 94
• Poland: +48 22 558 31 06
• Germany: +49 800 18 18 760
• New Zealand: +64 800 600 679

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succès dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.